• 1. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 2. Fe3O4/FeS2 heterostructures enable efficient oxygen evolution reaction?
  Xingqun Zheng,Lele Song,Xin Feng,Li Li,Zidong Wei J. Mater. Chem. A, 2020,8, 14145-14151
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 5. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Methyl 2-(4-bromo-1H-pyrazol-1-yl)acetate (CAS No. 1072944-71-8): A Versatile Intermediate in Modern Pharmaceutical Research

Methyl 2-(4-bromo-1H-pyrazol-1-yl)acetate, identified by its unique chemical identifier CAS No. 1072944-71-8, is a significant compound in the realm of pharmaceutical chemistry. This organic molecule, characterized by its ester functional group and a pyrazole core substituted with a bromine atom, has garnered considerable attention due to its utility as a building block in the synthesis of various bioactive molecules.

The compound's structure, featuring a 4-bromo-1H-pyrazol-1-yl moiety attached to an acetic acid methyl ester, makes it a valuable intermediate in the development of novel therapeutic agents. The bromine substituent at the 4-position of the pyrazole ring enhances its reactivity, allowing for further functionalization through cross-coupling reactions such as Suzuki-Miyaura and Buchwald-Hartwig couplings. These reactions are pivotal in constructing complex molecular architectures, which are often essential for achieving high affinity and selectivity in drug design.

In recent years, the demand for heterocyclic compounds in drug discovery has surged, with pyrazole derivatives being particularly prominent. Methyl 2-(4-bromo-1H-pyrazol-1-yl)acetate plays a crucial role in this context, serving as a precursor for synthesizing a wide range of pharmacologically relevant molecules. For instance, it has been employed in the development of kinase inhibitors, which are integral to treating cancers and inflammatory diseases. The pyrazole scaffold is known for its ability to modulate enzyme activity by binding to specific pockets within the target proteins.

One of the most compelling applications of Methyl 2-(4-bromo-1H-pyrazol-1-yl)acetate is in the synthesis of small-molecule inhibitors targeting protein-protein interactions (PPIs). PPIs are involved in numerous cellular processes and are often implicated in disease pathogenesis. By designing molecules that disrupt these interactions, researchers aim to develop treatments for conditions such as Alzheimer's disease and cancer. The brominated pyrazole derivative offers a versatile platform for generating such inhibitors due to its ability to undergo diverse chemical transformations while maintaining structural integrity.

Moreover, the compound's ester group provides a handle for further derivatization, enabling the creation of libraries of compounds with tailored properties. This flexibility is particularly valuable in high-throughput screening (HTS) campaigns, where large numbers of analogs are synthesized and tested for biological activity. The ease with which Methyl 2-(4-bromo-1H-pyrazol-1-yl)acetate can be modified allows researchers to rapidly explore structure-activity relationships (SAR), thereby accelerating the drug discovery process.

Recent advancements in computational chemistry have further enhanced the utility of this compound. Machine learning models and molecular docking simulations can be employed to predict the binding affinity of Methyl 2-(4-bromo-1H-pyrazol-1-yl)acetate derivatives to various targets. This approach not only saves time but also provides insights into optimal modifications that could improve potency and selectivity. Such computational tools are indispensable in modern drug design, complementing traditional wet-lab experimentation.

The synthesis of Methyl 2-(4-bromo-1H-pyrazol-1-yl)acetate itself is an elegant example of organic chemistry prowess. Typically, it involves the bromination of a pyrazole precursor followed by esterification. These steps highlight the compound's synthetic accessibility, making it an attractive choice for both academic and industrial research settings. The ability to produce this intermediate on scalable quantities ensures its readiness for preclinical and clinical studies.

In conclusion, Methyl 2-(4-bromo-1H-pyrazol-1-yl)acetate (CAS No. 1072944-71-8) is a cornerstone in contemporary pharmaceutical research. Its unique structural features and reactivity make it indispensable for developing novel therapeutic agents targeting a myriad of diseases. As research continues to evolve, this compound will undoubtedly remain at the forefront of medicinal chemistry innovation.

• 142890-12-8(methyl 2-(1H-pyrazol-1-yl)acetate)
• 1007550-84-6(2-(4-Bromo-1h-pyrazol-1-yl)acetaldehyde)
• 1199773-67-5(Tert-Butyl 2-(4-bromo-1H-pyrazol-1-yl)acetate)
• 1005566-07-3(methyl 2-(4-bromo-1H-pyrazol-1-yl)propanoate)
• 7593-56-8(Pyridazinium, 1-(2-methoxy-2-oxoethyl)-, bromide)
• 10199-61-8(Ethyl 2-(1H-pyrazol-1-yl)acetate)
• 82231-53-6((4-Bromo-1h-pyrazol-1-yl)acetic acid)
• 847818-49-9(4-bromo-1-(2-methoxyethyl)-1H-pyrazole)
• 1040377-17-0(ethyl 2-(4-bromopyrazol-1-yl)-2-methyl-propanoate)
• 82231-58-1(Ethyl 2-(4-bromo-1H-pyrazol-1-yl)acetate)